BOTOX® Prophylaxis in Patients With Chronic Migraine

CompletedOBSERVATIONAL
Enrollment

1,168

Participants

Timeline

Start Date

September 9, 2011

Primary Completion Date

May 12, 2015

Study Completion Date

May 12, 2015

Conditions
Migraine Disorders
Interventions
BIOLOGICAL

botulinum toxin Type A

155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.

Trial Locations (4)

Unknown

Munich

Oviedo

Stockholm

London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01432379 - BOTOX® Prophylaxis in Patients With Chronic Migraine | Biotech Hunter | Biotech Hunter